Purity ≥98%. Inhibits HCV NS3 serine proteases in cells and HCV replicon system in vivo. Has therapeutic potential in combination with IFN therapy. Investigated in clinical studies, in combination with current standard of care treatments for HCV Synonyms: (1R,2S,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; EBP 520; Sch 503034